Status:
UNKNOWN
Plasmapheresis Before Rituximab in Cryoglobulinemia
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Cryoglobulinemic Vasculitis
Eligibility:
All Genders
18+ years
Brief Summary
Initial worsening following initiation of rituximab therapy in patients with cryoglobulinemic vasculitis was described in 3.6% of cases. This worsening is often a serious condition, with high levels o...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- cryoglobulinemic vasculitis requiring rituximab treatment
- Patient ≥18 years old
- Exclusion Criteria:
- Patient who reject the study protocol
- Patient \< 18 years old
Exclusion
Key Trial Info
Start Date :
January 1 1999
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04692363
Start Date
January 1 1999
End Date
December 31 2021
Last Update
December 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295